GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Operating Income
中文

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Operating Income

: $2,451 Mil (TTM As of Dec. 2023)
View and export this data going back to 2010. Start your Free Trial

Takeda Pharmaceutical Co's Operating Income for the three months ended in Dec. 2023 was $461 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $2,451 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Takeda Pharmaceutical Co's Operating Income for the three months ended in Dec. 2023 was $461 Mil. Takeda Pharmaceutical Co's Revenue for the three months ended in Dec. 2023 was $7,718 Mil. Therefore, Takeda Pharmaceutical Co's Operating Margin % for the quarter that ended in Dec. 2023 was 5.98%.

Good Sign:

Takeda Pharmaceutical Co Ltd operating margin is expanding. Margin expansion is usually a good sign.

Takeda Pharmaceutical Co's 5-Year average Growth Rate for Operating Margin % was 9.70% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Takeda Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2023 was 3.36%. Takeda Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 26.48%.


Takeda Pharmaceutical Co Operating Income Historical Data

The historical data trend for Takeda Pharmaceutical Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,730.02 2,380.71 3,662.10 4,499.80 4,138.02

Takeda Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,089.50 1,130.92 1,192.51 -333.74 461.28

Takeda Pharmaceutical Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,451 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co  (NYSE:TAK) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Takeda Pharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=1845.1 * ( 1 - -72.63% )/( (96223.369 + 93624.34)/ 2 )
=3185.19613/94923.8545
=3.36 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=100591.085 - 3728.878 - ( 2257.817 - max(0, 16014.184 - 16653.022+2257.817))
=96223.369

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=98783.156 - 4140.199 - ( 2204.478 - max(0, 15850.425 - 16869.042+2204.478))
=93624.34

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Takeda Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3551.236/( ( (12811.634 + max(18.560000000003, 0)) + (12789.831 + max(1199.467, 0)) )/ 2 )
=3551.236/( ( 12830.194 + 13989.298 )/ 2 )
=3551.236/13409.746
=26.48 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5108.911 + 7818.093 + 1246.759) - (3728.878 + 0 + 10426.325)
=18.560000000003

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4974.459 + 8123.544 + 1380.086) - (4140.199 + 0 + 9138.423)
=1199.467

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Takeda Pharmaceutical Co's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=461.275/7717.561
=5.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Takeda Pharmaceutical Co Operating Income Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Headlines

From GuruFocus